What is he best known for?
The fields of study he is best known for:
Paul D. Bieniasz focuses on Virology, Viral replication, Tetherin, Virus and Viral envelope.
He has researched Virology in several fields, including Epitope, Genetics, Antibody and Protein domain.
The study incorporates disciplines such as Interferon, Reverse transcriptase and Gene in addition to Viral replication.
His Tetherin study integrates concerns from other disciplines, such as Human Immunodeficiency Virus Proteins, Ebola virus, Cell membrane and Function.
His work deals with themes such as RNA and In vitro, which intersect with Virus.
Paul D. Bieniasz interconnects Budding, Cell biology, Protein targeting, Virion assembly and Consensus sequence in the investigation of issues within Viral envelope.
His most cited work include:
- A diverse range of gene products are effectors of the type I interferon antiviral response (1512 citations)
- Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu (1485 citations)
- Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. (1084 citations)
What are the main themes of his work throughout his whole career to date?
Paul D. Bieniasz mainly focuses on Virology, Antibody, Virus, Cell biology and Viral replication.
His Virology research is multidisciplinary, relying on both Epitope, Gene and Severe acute respiratory syndrome coronavirus 2.
The Antibody study which covers Coronavirus that intersects with Avidity.
His work in Virus tackles topics such as Antigen which are related to areas like Titer.
His study in Cell biology is interdisciplinary in nature, drawing from both Ubiquitin and Cell membrane.
His work is dedicated to discovering how Viral replication, Interferon are connected with Innate immune system and other disciplines.
He most often published in these fields:
- Virology (96.53%)
- Antibody (51.04%)
- Virus (41.67%)
What were the highlights of his more recent work (between 2018-2021)?
- Antibody (51.04%)
- Virology (96.53%)
- Virus (41.67%)
In recent papers he was focusing on the following fields of study:
Paul D. Bieniasz spends much of his time researching Antibody, Virology, Virus, Neutralization and Severe acute respiratory syndrome coronavirus 2.
His research investigates the connection between Antibody and topics such as Coronavirus that intersect with issues in Avidity.
Paul D. Bieniasz is involved in the study of Virology that focuses on Vaccination in particular.
His Virus study incorporates themes from RNA, Antigen and Immunity.
Paul D. Bieniasz combines subjects such as Spike Protein and Immune system with his study of Severe acute respiratory syndrome coronavirus 2.
His research integrates issues of Interferon, Ex vivo, Reverse transcription polymerase chain reaction and Cell biology in his study of Viral replication.
Between 2018 and 2021, his most popular works were:
- Convergent antibody responses to SARS-CoV-2 in convalescent individuals. (708 citations)
- Convergent antibody responses to SARS-CoV-2 in convalescent individuals. (708 citations)
- Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. (309 citations)
In his most recent research, the most cited papers focused on:
Paul D. Bieniasz mainly investigates Antibody, Virology, Neutralization, Virus and Epitope.
The Antibody study combines topics in areas such as Immunity and Coronavirus.
His Virology study combines topics from a wide range of disciplines, such as Potency and Monoclonal antibody.
As part of the same scientific family, he usually focuses on Neutralization, concentrating on Titer and intersecting with Immunization.
In his work, Seroprevalence, Viral replication, Protein domain and Infectious disease is strongly intertwined with Vaccination, which is a subfield of Virus.
His research in Epitope intersects with topics in Antibody response, Spike Protein, Coronavirus disease 2019, Severe acute respiratory syndrome coronavirus 2 and Viral entry.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
